Oxford BioMedica PLC (OXBDF)

[marcusl2]

Fast forward to 1:01:57 to listen to our interview with the #BBCRadioOxford, where Chief Technical Officer, James Miskin discusses Kymriah and the NHS’s approval to treat children and young people with a form of leukaemia hTTps://bbc.in/2oMr88E #genetherapy

Canadian approval now:
HTTPS://www.newswire.ca/news-releases/novartis-receives-health-canada-approval-of-its-car-t-cell-therapy-kymriah-tisagenlecleuceli-692581041.html

Novartis receives Health Canada approval of its CAR-T cell therapy, Kymriah™ (tisagenlecleucel)I

Health Canada has approved Kymriah for use in pediatric and young adult patients 3 to 25 years of age with B-cell acute lymphoblastic leukemia (ALL) who are refractory, have relapsed after allogenic stem cell transplant (SCT) or are otherwise ineligible for SCT, or have experienced second or later relapse; and for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphomai.

hTTps://markets.businessinsider.com/news/stocks/novartis-receives-health-canada-approval-of-its-car-t-cell-therapy-kymriah-tisagenlecleucel-i-1027513253


hTTps://phss.co.uk/events/EventDetails.aspx?id=1038313

Lonza and Oxford Biomedica attending